Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
February 2021
Notwithstanding these limitations, disproportionality analysis still remains a crucial tool for detecting potential safety signals associated with drugs and guiding further investigations [Reference Chen, Ding, Fu and Xiao16, Reference Zhou, Peng, Lin, Jiang, Peng and Gu29, Reference Blau, Tella, Taylor and Rother33, Reference Ding, Chen, Yang, Fang, Cao and Liu52]
Retatrutide is an unlicensed investigational triple agonist (GLP-1, GIP, glucagon) with no MHRA or EMA marketing authorisation
doi:10.1016/bs.pbr.2021.04.005
US$ 29.89
US$ 22.47
&srotate=0)
US$ 24.17
US$ 28.31
US$ 25.80
